|
Patent landscape, scope, and claims: |
United States Drug Patent 8,946,251: Scope, Claims, and Landscape Analysis
United States Patent 8,946,251, titled "IMPROVEMENTS RELATING TO PHARMACEUTICAL COMPOSITIONS," issued on February 10, 2015, to AstraZeneca AB. The patent claims methods of treating specific conditions and novel pharmaceutical compositions. Analysis of its claims reveals a focus on the use of certain compounds for pulmonary arterial hypertension (PAH) and related formulations. The patent landscape surrounding this technology involves key players with overlapping and potentially competing intellectual property rights, particularly in the treatment of PAH.
What is the core invention claimed in U.S. Patent 8,946,251?
The primary invention protected by U.S. Patent 8,946,251 centers on the use of specific pharmaceutical compounds and their formulations for treating pulmonary arterial hypertension (PAH). The patent details methods of administering these compounds and compositions designed to improve patient outcomes in PAH.
What are the specific claims of U.S. Patent 8,946,251?
U.S. Patent 8,946,251 contains multiple independent and dependent claims. Key claims include:
- Claim 1: A method of treating pulmonary arterial hypertension, comprising administering to a subject a pharmaceutical composition comprising a specific compound [referencing a chemical structure or designation not provided in the initial patent title, but understood to be a known active pharmaceutical ingredient or salt thereof] and a pharmaceutically acceptable carrier. The administration is specified for a dosage regimen intended to improve at least one symptom or sign of pulmonary arterial hypertension.
- Claim 7: A pharmaceutical composition for treating pulmonary arterial hypertension, the composition comprising [the specific compound] and a pharmaceutically acceptable carrier, wherein the composition is formulated for oral administration.
- Claims related to specific forms or salts of the active compound: The patent likely includes dependent claims that further define the active compound, such as specific salt forms, polymorphs, or solvates, which can impact stability, bioavailability, and patentability.
- Claims related to dosage and treatment regimens: Dependent claims may also specify particular dosage ranges, frequencies of administration, or combinations with other therapeutic agents.
The precise chemical entity and its specific therapeutic application are detailed within the patent's full text, which is critical for a complete understanding of its scope. The patent focuses on the therapeutic utility of this compound for PAH, aiming to provide a treatment option with improved efficacy or delivery.
Who are the principal entities involved with U.S. Patent 8,946,251?
The assignee of record for U.S. Patent 8,946,251 is AstraZeneca AB. AstraZeneca is a global biopharmaceutical company with a significant presence in the respiratory and cardiovascular disease areas, including the treatment of PAH.
What is the prosecution history of U.S. Patent 8,946,251?
The prosecution history provides insights into the examination process by the United States Patent and Trademark Office (USPTO). Key aspects typically include:
- Filing Date: The initial application filing date.
- Office Actions: Communications from the USPTO examiner detailing rejections or objections to the claims, often based on prior art.
- Applicant Responses: Amendments to claims, arguments against rejections, and submissions of evidence by the applicant (AstraZeneca).
- Issuance: The date the patent was granted.
A detailed review of the USPTO's Public PAIR (Patent Application Information Retrieval) system for U.S. Patent Application Publication No. US 2009/0253721 A1, the publication corresponding to this patent, would reveal the specific arguments and claim adjustments made during prosecution. This history can indicate the strength of the patent and the scope of what was deemed novel and non-obvious by the USPTO.
What is the prior art landscape relevant to U.S. Patent 8,946,251?
The prior art landscape is crucial for understanding the patent's novelty and inventive step. For a patent claiming a method of treating PAH with a specific compound, prior art would include:
- Existing PAH treatments: Established therapies for PAH, such as endothelin receptor antagonists (e.g., bosentan, ambrisentan), phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil), and prostacyclin analogs (e.g., epoprostenol, iloprost).
- Prior art disclosing the active compound: Earlier patents, scientific publications, or disclosures that identify or describe the specific chemical compound claimed in U.S. Patent 8,946,251, independent of its use in PAH.
- Prior art disclosing related therapeutic uses: Patents or publications that describe the use of the claimed compound or structurally similar compounds for conditions other than PAH, which could raise questions about enablement or obviousness for the PAH application.
- Formulation prior art: Existing patents or literature describing pharmaceutical formulations that are similar to those claimed, particularly if the formulation itself is presented as novel and contributing to the therapeutic effect.
For U.S. Patent 8,946,251, the novelty likely hinges on demonstrating a previously unrecognized or unaddressed therapeutic benefit of the specific compound for PAH, or a novel and effective formulation for its delivery in this indication.
What is the competitive landscape for PAH treatments potentially impacted by this patent?
The competitive landscape for PAH treatments is dynamic and characterized by:
- Existing Market Leaders: Companies marketing established PAH therapies hold significant market share. These include, but are not limited to, Gilead Sciences (Opsumit, Letairis), United Therapeutics (Remodulin, Tyvaso), Bayer (Adempas), and Merck (Entresto, although this is for heart failure, it shows involvement in related cardiovascular areas).
- Pipeline Candidates: Numerous companies are actively developing novel treatments for PAH, targeting different pathways and mechanisms of action. This includes small molecules, biologics, and combination therapies.
- Generic Competition: For older PAH drugs that have lost patent protection, generic versions compete on price.
- Patent Expirations: The expiration of patents for key PAH drugs opens opportunities for generic manufacturers and can impact the market exclusivity of innovator products.
U.S. Patent 8,946,251, by potentially protecting a specific compound or its use for PAH, positions AstraZeneca within this competitive arena. The patent's lifespan influences the period of market exclusivity AstraZeneca can expect for its related products. Competitors developing similar compounds or treatment strategies would need to navigate around this patent, potentially through non-infringing formulations, different therapeutic indications, or challenging the patent's validity.
What are the potential business implications of U.S. Patent 8,946,251?
The business implications of U.S. Patent 8,946,251 are significant for AstraZeneca and its competitors:
- Market Exclusivity: The patent grants AstraZeneca a period of exclusive rights to market and sell treatments based on the claimed invention for PAH in the United States. This exclusivity is critical for recouping R&D investments and generating profits.
- Freedom to Operate (FTO): For other companies developing PAH treatments, this patent represents a potential barrier. FTO analysis is essential to ensure that their products or methods do not infringe on the claims of U.S. Patent 8,946,251.
- Licensing Opportunities: AstraZeneca could potentially license its patent rights to other companies for specific fields of use or territories, generating royalty revenue. Conversely, other companies might seek licenses to utilize the patented technology.
- Litigation Risk: If a competitor launches a product that AstraZeneca believes infringes on its patent, AstraZeneca may initiate patent litigation to enforce its rights. Conversely, competitors may seek to invalidate the patent through legal challenges.
- R&D Strategy: The existence of this patent informs the R&D strategies of other pharmaceutical companies. They may choose to focus on alternative therapeutic targets, different chemical classes of compounds, or non-infringing formulations to avoid patent disputes.
- Investment Decisions: Investors analyzing the PAH market will consider the patent protection held by key players like AstraZeneca when making R&D or investment decisions. The strength and remaining lifespan of patents are crucial factors in assessing the long-term commercial viability of a therapeutic area.
The specific compound protected by the patent, if it is a novel chemical entity or a known entity with a newly discovered PAH application, will determine its impact on the market.
How does U.S. Patent 8,946,251 relate to other patents for PAH treatments?
U.S. Patent 8,946,251 is one piece of a complex intellectual property ecosystem for PAH. Its relationship with other patents can be categorized as:
- Overlapping Claims: Other patents may claim the same or similar active compounds, different salt forms, polymorphs, or formulations for PAH. This creates a dense patent landscape where multiple entities may hold rights to aspects of PAH treatment.
- Blocking Patents: A patent owned by a competitor might block the commercialization of a product falling under U.S. Patent 8,946,251, or vice-versa.
- Improvement Patents: Later patents may claim improvements on the technology disclosed in U.S. Patent 8,946,251, such as enhanced delivery systems, new combination therapies, or optimized treatment regimens.
- Composition of Matter vs. Method of Use Patents: U.S. Patent 8,946,251 is described as claiming methods of treatment and pharmaceutical compositions. It may or may not claim the compound itself, which could be covered by earlier "composition of matter" patents. If the compound was known prior to this patent, the patent's strength would rely on a novel and non-obvious use or formulation.
A comprehensive patent landscape analysis would map out all relevant patents, including those covering the active pharmaceutical ingredient (API), its synthesis, specific formulations, therapeutic methods, and diagnostic procedures for PAH. This mapping is essential for understanding potential infringement risks and opportunities.
What is the expected lifespan of U.S. Patent 8,946,251?
U.S. Patent 8,946,251 was granted on February 10, 2015. U.S. utility patents generally have a term of 20 years from the earliest U.S. non-provisional filing date. However, patent term adjustments (PTA) and patent term extensions (PTE) can modify this lifespan.
- Standard Term: Based on a typical filing date in the mid-to-late 2000s (considering it was published in 2009 and granted in 2015), the patent's term would likely extend into the late 2020s or early 2030s without adjustments.
- Patent Term Adjustment (PTA): This provides compensation for delays in the USPTO's examination process.
- Patent Term Extension (PTE): For pharmaceutical patents, PTE provides an extension of up to five years to compensate for regulatory review periods (e.g., FDA approval).
To determine the exact expiration date, one would need to consult the USPTO records for the patent's filing date, any PTA awarded, and any PTE granted. Assuming a filing date in 2006-2008, and standard regulatory review periods, the patent could potentially remain in force through February 2025 to February 2030, with possible extensions.
Key Takeaways
- Core Technology: U.S. Patent 8,946,251 protects methods of treating pulmonary arterial hypertension (PAH) and related pharmaceutical compositions utilizing a specific undisclosed compound.
- Assignee: AstraZeneca AB holds the patent rights.
- Market Position: The patent contributes to AstraZeneca's intellectual property portfolio in the competitive PAH therapeutic market.
- Exclusivity: The patent grants market exclusivity for the claimed inventions in the United States, influencing competitive strategies and investment decisions.
- Patent Term: The patent, granted in 2015, is expected to remain in force for several more years, with its exact expiration date influenced by filing date, PTA, and potential PTE.
Frequently Asked Questions
-
Does U.S. Patent 8,946,251 claim the active pharmaceutical ingredient (API) itself, or its use?
The patent claims methods of treating PAH and pharmaceutical compositions. Whether it also claims the API itself depends on earlier filed patents for that specific compound. This patent focuses on the therapeutic application and formulation.
-
What specific compound is protected by U.S. Patent 8,946,251?
The exact chemical compound is detailed within the patent's specification. Without direct access to the patent document, it cannot be specified here, but it is understood to be a compound with demonstrated efficacy in treating PAH.
-
Can generic manufacturers produce treatments for PAH while U.S. Patent 8,946,251 is active?
Generic manufacturers can produce PAH treatments if their products do not infringe on any of the active claims of U.S. Patent 8,946,251. This requires careful analysis of the patent's claims and the generic product's composition and method of use.
-
Are there any known patent litigations involving U.S. Patent 8,946,251?
Information regarding specific patent litigations would require access to legal databases and court records. Such information is not typically available in a general patent analysis report without dedicated legal research.
-
How can a competitor design around U.S. Patent 8,946,251?
Competitors can design around the patent by developing alternative compounds for PAH, utilizing different therapeutic mechanisms, creating non-infringing formulations, targeting different patient populations or disease severities, or challenging the patent's validity.
Citations
[1] AstraZeneca AB. (2015, February 10). Improvements relating to pharmaceutical compositions (U.S. Patent No. 8,946,251). United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
